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Objectives: Complications in instrumental spinal surgeries (ISS) pose a consider-
able burden on patients. Necessary reoperations are associated with significant 
resource utilization and cost and from the perspective of the German Statutory 
Health Insurance (SHI). Dependable data on the frequency of reoperations and 
associated costs are lacking for Germany. The aim of this study was to estimate 
the incidence of ISS and consecutive reoperations, and to calculate the related 
costs. MethOds: We conducted a retrospective claims data analysis using the 
Health Risk Institute research database, which contains anonymized claims data 
and covers approximately 5.42% of the German population. The study period 
comprised 01 January 2009 to 31 December 2011. An algorithm of operation and pro-
cedure codes (OPS) identified primary ISS and following reoperations. Reoperation 
rates were calculated for an individual period of 12 months after the primary ISS in 
2010. Annual costs for reoperations were calculated based on group comparison of 
patients with reoperation and those without reoperation (control group). Existing 
differences in cost levels in the year before the primary ISS were adjusted by the 
difference in differences approach. Results: A total of 3,316 individuals had a 
primary ISS in 2010. The reoperation rate was 9.98% (95% CI = 8.98% to 11.02%). 
Mean cost per ISS was € 11,331 for all patients (€ 13,358 reoperation group, € 11,106 
control group). The mean adjusted annual cost for a reoperation was € 11,370, with 
€ 8,432 directly attributed to the reoperation procedure and € 2,938 to excess costs 
in the first year after the primary ISS. cOnclusiOns: The direct cost of ISS has a 
significant impact on health insurance budgets. With 10% of primary ISS patients 
requiring a reoperation in Germany, their associated annual costs are relevant from 
the SHI perspective. As demonstrated elsewhere, these cost might be partly avoid-
able by using intra-operative 3-D imaging with navigation.
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Objectives: This study aims to estimate the incidence and costs of osteoporotic 
fractures in The Netherlands in 2010 and project them to 2030. MethOds: The 
incidence and health care costs of fractures were derived from claims data of 
all health care insurers in The Netherlands. We obtained 5-year age- and gen-
der-specific costs of patients with and without fractures. Cost included hospi-
tal admission, physical therapy, occupational therapy, general practitioner and 
medication. In order to attribute fractures to osteoporosis we used a large dataset 
from a general hospital that included patients with a fracture screened with Dexa 
scan. Future projections were based on four different scenarios: 1. demographic 
scenario, 2. demographic+trend in incidence scenario, 3. demographic+trend in 
incidence+trend in cost scenario, and 4. increased treatment scenario. Results: 
Of all registered fractures 32% could be attributed to osteoporosis. In women this 
percentage was larger than in men (36 versus 21 %). This resulted in an incidence 
for all osteoporotic fractures of 964 per 100.000 in women and 245 per 100.000 in 
men for 2010. Over time (2010-2030) the overall increase in incidence of osteo-
porotic fractures was 40% (scenario 1). The increase in hip fractures ranged from 
60% (scenario 1) to 79% (scenario2). In 2010 approximately 200 million Euros was 
spend on treatment of osteoporotic fractures. The costs for osteoporotic fractures 
increased with 50% from 2010 till 2030 (scenario 1). The increase in costs for hip 
fractures was highest, ranging from 60% (scenario1) to 148% (scenario 3&4 com-
bined), resulting in cost estimates in 2030 of 161 and 249 million, respectively. 
Prevention of osteoporotic fractures in general can lead to cost-savings of 92 mil-
lion in 2030 (scenario 4 & 1 combined). cOnclusiOns: The expected high increase 
in incidence and costs of osteoporotic fractures calls for a wider use of prevention 
and treatment options.
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Objectives: Ankylosing spondylitis (AS) entails an individual burden to patients 
and ties up resources. This study aimed to assess the total costs of AS, includ-
ing the indirect burden of AS patients in Hungary and to obtain an overview of 
patients’ status, demographics, morbidity, working capacity and other charac-
teristics. MethOds: Between January–March 2014, a questionnaire survey was 
conducted among AS patients, which was filled out voluntarily and anonymously. 
Missing data was not imputed in the analysis; considered patient number is pre-
sented next to results if lower than total patient number. Results: 152 patients 
completed the questionnaire, of which 37% were women. Mean age was 51 years 
(Standard Deviation [SD]: 13 years) and average disease duration was 17 years 
(SD: 12 years). At primary diagnosis of AS, 80% of patients had a full-time job, 2% 
a part-time job, and only 8% received disability pension. At time of survey, only 
36% of patients worked full-time, 1% part-time, and the proportion of disability 
pensioners increased to 42%. Cost calculation results* showed that the average 
annual total cost per AS patient was 5,155€ . Within this, average annual direct non-
medical cost was over 1,976€ and average annual indirect cost per patient was 
approximately 3,129€ (145 patients). Wage loss due to disability pension generated 
the highest average annual indirect cost per patient (3,290€ – 124 patients). In the 
working-age population (118 patients, 31–62 years), total average cost per patient 
was 5,996€ . cOnclusiOns: Due to their disease, AS patients can become par-
tially or completely disabled, which imposes a significant burden directly on their 
environment and indirectly to society. Average costs were associated with disease 
duration. Patients may already be driven out from the labour market in their active 
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Objectives: Lumbar spinal stenosis (LSS) occurs as a degeneration of the spine 
in aging populations. Treatment options comprise surgical and non-surgical 
intervention. The aim of this study was to compare annual costs between LSS 
patients treated with instrumental spinal surgery (ISS) and those non-surgically 
treated. MethOds: A retrospective claims data analysis was conducted using 
anonymized claims data from the Health Risk Institute research database. The study 
period comprised 01 January 2009 to 31 December 2011. LSS patients receiving an 
ISS were compared to an age and gender matched non-operated control group with 
comparable disease state. Patients were identified by ICD-10-GM code M48.0* in the 
inpatient setting. Operation and procedure codes (OPS) were used to identify ISS. 
Comparable disease state was achieved by matching total costs in an individual 
period of 12 months before the first LSS caused hospitalization. Annual costs after 
surgical treatment were compared for LSS patients receiving ISS and those with no 
surgical treatment. Results: A total of 2,027 patients with LSS were identified in 
2010 records. Surgical treatment with ISS was applied in 542 cases whereas 1,485 
individuals received non-surgical treatment. After matching both groups for age, 
gender, and comparable disease state, 393 patients in each group were available for 
the cost comparison. Mean annual costs were € 8,458 higher in the ISS-treated group; 
clearly due to average ISS-cost of € 9,644. In contrast, costs for outpatient care and 
pharmaceuticals decrease after the surgery. cOnclusiOns: Surgical treatment for 
LSS patients exceeds the cost of non-surgical treatment in the first year after sur-
gery. A cost offset is not achievable in this period due to the high cost of the surgical 
intervention. Nevertheless, cost savings were already observed in pharmaceutical 
therapy and outpatient care. Further research is needed to determine if overall cost 
savings could be achieved in an extended timeframe.
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Objectives: The purpose of this study was to estimate the annual costs and the 
cost per responder for psoriatic arthritis (PsA) patients treated with apremilast, 
etanercept, and adalimumab in adults with PsA in the United States. MethOds: 
Comparative efficacy data were obtained from a Bayesian network meta-analysis 
of biologic and non-biologic disease-modifying antirheumatic drugs as of October 
2013. The primary outcome was ACR20 response at Week 24. Response rate dif-
ferences from the clinical trials were assumed to be maintained for 52 weeks. US 
wholesale acquisition cost as of June 2014 and approved labeled dosing were used 
to derive drug treatment costs. Results: At Week 24, the adjusted ACR20 response 
rate was 40.3% for apremilast, 53.4% for etanercept, and 57.8% for adalimumab. 
The cost per ACR20 responder at Week 24 was $23,562 for apremilast, $30,346 for 
etanercept, and $25,978 for adalimumab. By Week 52, the cost per ACR20 responder 
was $53,704 for apremilast, $65,750 for etanercept, and $56,273 for adalimumab. The 
annual cost to achieve 100 responders was $5,370,387 for apremilast, $6,574,981 for 
etanercept, and $5,627,336 for adalimumab. cOnclusiOns: Apremilast had the 
lowest wholesale acquisition costs per ACR20 responder and the lowest annual cost 
to achieve 100 ACR20 responders, as compared with etanercept and adalimumab 
through 52 weeks in PsA patients.
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Objectives: Direct non-medical costs may be difficult to assess, so these are often 
disregarded in cost-of-illness studies. This analysis aims to estimate the annual 
direct non-medical costs of treating a patient with Rheumatoid Arthritis (AR) in 
Portugal, per level of disease activity. MethOds: Patients with RA followed by 5 
different rheumatologists across the country, were asked to participate in a survey, 
and informed consent was given by all patients. Besides socio-economic data, the 
survey included questions regarding the following cost components: number of 
medical appointments and treatments attended by the patient and its associated 
travel expenses; expenditures related to adaptations made to their homes and the 
purchase of medical devices; amount of domiciliary support received, both paid 
and unpaid. In case of paid domiciliary support patients were also asked about the 
associated amount. That figure was then used in order to assess the value of unpaid 
domiciliary support. Disease activity was measured by the DAS28 score. Results: 
Our final sample consists of 90 patients and descriptive statistics are in line with 
RA epidemiology (73 women, mean age 56.9). The percentage of patients with low 
disease activity was 27.7%, whereas, of 43.3% and 28.8% for those with moderate 
and high disease activity, respectively. Estimated direct non-medical costs ranged 
from € 1,339 to € 5,475 per year, for patients with low and high disease activity, respec-
tively. More than 70% of these costs were related to paid and unpaid domiciliary 
support. cOnclusiOns: Direct non-medical costs are positively associated with 
disease activity. Estimated costs have a non-negligible magnitude and are entirely 
borne by patients. Our results confirm the heavy economic burden that RA places 
on patients and their families.
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